MTOR and Burkitt lymphoma: In vitro studies suggest that PI3K inhibition has greater potency in ABC‐DLBCL, while AKT inhibition is most effective in PTEN‐deficient (mostly GCB‐) DLBCL.198 mTOR inhibition, on the other hand, showed moderate efficacy in DLBCL with 28%‐29% or 37.5% ORR, alone or in combination with the anti‐CD20 monoclonal antibody Rituximab, respectively.195 Based on their genomic profile, BL patients would also be expected to respond to mTOR inhibition.